India’s platinum shortage triggers chemo drug crisis, warning U.S. of supply risks

In India, a sudden doubling of platinum prices disrupted the supply of cisplatin and carboplatin, two inexpensive generic chemotherapy drugs that rely on the metal. Some producers reduced output while one temporarily stopped production, and the government responded by lifting price ceilings by 50 % to restore availability. The situation illustrates that merely designating platinum as a critical mineral does not protect downstream medicines, a point relevant to the United States, which has added platinum to its critical minerals list and is creating a $10 billion strategic reserve called Project Vault.

Analysts note that a mineral reserve safeguards raw material but cannot ensure the full pharmaceutical supply chain, and that medical necessity often fails to generate a strong market signal for manufacturers. They suggest the Department of Health and Human Services should help define medical demand within the reserve and consider subsidies or allocations to guarantee access during disruptions. The Indian case serves as a warning that without such measures, patients could again face shortages of life-saving chemotherapy.